Kim H - Search Results

1

Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.

Kim H, Lim DH, Kwon YS, Kim MA, Park KU. Kim H, et al. Among authors: kim ma. Anticancer Res. 2023 May;43(5):2343-2349. doi: 10.21873/anticanres.16399. Anticancer Res. 2023. PMID: 37097676

2

Dose Modification of Etoposide plus Platinum in Elderly Patients with Extensive-Disease Small-Cell Lung Cancer.

Kim H, Choi E, Heo MH, Kim JY, Park KU. Kim H, et al. Among authors: kim jy. Oncology. 2022;100(6):313-319. doi: 10.1159/000524476. Epub 2022 Apr 7. Oncology. 2022. PMID: 35390786

3

Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer.

Kim H, Kim JY, Park KU. Kim H, et al. Among authors: kim jy. Oncology. 2023;101(1):41-48. doi: 10.1159/000527525. Epub 2022 Oct 18. Oncology. 2023. PMID: 36257294 Free article.

4

Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.

Kim H, Kwon M, Kim B, Jung HA, Sun JM, Lee SH, Park K, Ahn MJ. Kim H, et al. Among authors: kim b. BMC Cancer. 2020 Aug 5;20(1):727. doi: 10.1186/s12885-020-07214-4. BMC Cancer. 2020. PMID: 32758163 Free PMC article.

5

Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.

Kim H, Kim J, Byeon S, Jang KT, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim ST. Kim H, et al. Among authors: kim st, kim j. Oncology. 2021;99(6):365-372. doi: 10.1159/000514404. Epub 2021 Mar 17. Oncology. 2021. PMID: 33730723

6

The prognostic factors influencing overall survival in uterine cervical cancer with brain metastasis.

Kim H, Lee KK, Heo MH, Kim JY. Kim H, et al. Among authors: kim jy. Korean J Intern Med. 2019 Nov;34(6):1324-1332. doi: 10.3904/kjim.2018.051. Epub 2018 Oct 26. Korean J Intern Med. 2019. PMID: 30360020 Free PMC article.

7

Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients.

Kim J, Byeon S, Kim H, Yeo JH, Hong JY, Lee J, Lim HY, Kang WK, Kim ST. Kim J, et al. Among authors: kim h, kim st. Target Oncol. 2020 Apr;15(2):203-209. doi: 10.1007/s11523-020-00713-1. Target Oncol. 2020. PMID: 32314267

8

ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy.

Kim H, Kim ST, Yoo KH, Hong JY, Park YS, Lim HY, Park JO. Kim H, et al. Among authors: kim st. In Vivo. 2021 Jan-Feb;35(1):499-505. doi: 10.21873/invivo.12284. In Vivo. 2021. PMID: 33402502 Free PMC article.

9

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.

Kim H, Lee SJ, Lee IK, Min SC, Sung HH, Jeong BC, Lee J, Park SH. Kim H, et al. Int J Mol Sci. 2020 Apr 18;21(8):2825. doi: 10.3390/ijms21082825. Int J Mol Sci. 2020. PMID: 32325639 Free PMC article.

10

Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study.

Byeon S, Kim H, Kim J, Kwon M, Hur JY, Jeon HG, Jeon SS, Lee HM, Park SH. Byeon S, et al. Among authors: kim h, kim j. Investig Clin Urol. 2020 Nov;61(6):588-593. doi: 10.4111/icu.20200214. Epub 2020 Sep 8. Investig Clin Urol. 2020. PMID: 32985144 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

101,778 results

Search Page

Filters